» Articles » PMID: 18184280

Concepts and Mechanisms of Migraine Chronification

Overview
Journal Headache
Publisher Wiley
Specialties Neurology
Psychiatry
Date 2008 Jan 11
PMID 18184280
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Migraine is a chronic recurrent disorder with episodic manifestations that is progressive in some individuals. Migraine progresses clinically, physiologically, and anatomically. Progression may be a consequence of the mechanisms that generate the migraine attacks (eg, cortical spreading depression) or it may be a function of the activations generated by the attacks (eg, lesions in the periaqueductal gray area), a hypothesis supported by the increase in lesions with attack frequency. Progression may also be partially explained by common genetic or environmental risk factors. Finally, migraine with aura is associated with an elevated Framingham score and with risk factors for cardiovascular disease. Research on this issue is in its infancy and cautions are necessary before extrapolating this information into clinical practice.

Citing Articles

A study to investigate the prevalence of headache disorders and migraine conducted using medical claims data and linked results from online surveys: post-hoc analysis of other headache disorders.

Takeshima T, Hirata K, Igarashi H, Sakai F, Sano H, Kondo H BMC Neurol. 2024; 24(1):176.

PMID: 38796414 PMC: 11127369. DOI: 10.1186/s12883-024-03675-3.


Unsatisfactory response to acute medications does not affect the medication overuse headache development in pediatric chronic migraine.

Frattale I, Ferilli M, Ursitti F, Sforza G, Monte G, Proietti Checchi M J Headache Pain. 2024; 25(1):61.

PMID: 38649822 PMC: 11036745. DOI: 10.1186/s10194-024-01766-7.


Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview.

Mazzacane F, Vaghi G, Ramusino M, Perini G, Costa A J Headache Pain. 2024; 25(1):13.

PMID: 38311745 PMC: 10840219. DOI: 10.1186/s10194-024-01720-7.


Association of dietary patterns with migraine: A matched case-control study.

Martami F, Togha M, Qorbani M, Shahamati D, Salami Z, Shab-Bidar S Curr J Neurol. 2023; 22(2):87-95.

PMID: 38011363 PMC: 10460918. DOI: 10.18502/cjn.v22i2.13333.


Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews.

Palacios-Cena D, Ordas-Bandera C, Casas-Limon J, Perez-Corrales J, Gueita-Rodriguez J, Arias-Navalon J Ann Med. 2023; 55(2):2255215.

PMID: 37708876 PMC: 10936648. DOI: 10.1080/07853890.2023.2255215.